However, increased levels of NCOA2 and NCOA3 were associated with reduced DFS, which is consistent with the results of previous reports.(52,53) Furthermore, we identified that the expression of both is related to clinical T3 staging, consistent with earlier findings by our group.(54) Therefore, even at low levels in the primary tumor, these genes can predict the clinical evolution of the disease from its initial presentation, mainly due to the accumulation and direction of their functions, including metabolic functions, to promote PCa progression. Here, NCOA2 is linked to posterior cortical atrophy.